10-Q: Iris Acquisition Corp Reports Q3 2024 Results Amidst Business Combination Extension and Delisting

Iris Acquisition Corp's Q3 2024 report reveals a net loss, ongoing business combination efforts, and a delisting from Nasdaq, with trading now on the OTC Pink Marketplace.

Summary

• Iris Acquisition Corp reported a net loss of $642,900 for the three months ended September 30, 2024, and a net loss of $2,035,985 for the nine months ended September 30, 2024.
• The company's operating cash balance was $358,181, which includes $32,580 of restricted cash for tax payments, and a working capital deficit of approximately $7,141,435 as of September 30, 2024.
• The company has extended the deadline to complete its initial business combination to December 31, 2024.
• Iris Acquisition Corp was delisted from Nasdaq and is now trading on the OTC Pink Marketplace.
• The company is pursuing a business combination with Liminatus Pharma, LLC, with the agreement being amended multiple times to extend the closing date.
• The company has faced significant redemptions of its Class A common stock, reducing the number of outstanding shares.
• The company has incurred significant costs in pursuit of its acquisition plans, raising substantial doubt about its ability to continue as a going concern.
• The company has a promissory note with a related party with a balance of $1,453,720 and a promissory note with Liminatus with a balance of $3,118,500.
• The company has identified material weaknesses in its internal controls over financial reporting.

Sentiment

Score: 3

Explanation: The document presents a concerning picture with significant net losses, a substantial working capital deficit, delisting from Nasdaq, and material weaknesses in internal controls. The company's ability to continue as a going concern is in doubt, and the business combination faces significant challenges. The sentiment is negative due to the numerous issues and uncertainties.

Positives

• The company continues to pursue a business combination with Liminatus Pharma, LLC.
• The company has secured extensions to the business combination deadline, providing more time to complete the transaction.
• The company has amended the PIPE Equity Subscription Agreement to increase the PIPE Investors committed purchase of PIPE Shares from 1,500,000 to 2,500,000, and increase the PIPE Equity Investment from $15,000,000 to $25,000,000 (later reduced to 1,500,000 shares and $15,000,000).

Negatives

• The company has incurred significant net losses for both the three and nine month periods ending September 30, 2024.
• The company has a substantial working capital deficit of approximately $7,141,435.
• The company was delisted from Nasdaq and is now trading on the OTC Pink Marketplace.
• The company has identified material weaknesses in its internal controls over financial reporting.
• The company's ability to continue as a going concern is in doubt due to significant costs and the approaching deadline for the business combination.
• The company has faced significant redemptions of its Class A common stock, reducing the number of outstanding shares.

Risks

• The company may not be able to complete its initial business combination by the extended deadline of December 31, 2024.
• The company's working capital deficit and limited cash reserves may hinder its ability to operate effectively.
• The company's delisting from Nasdaq could negatively impact investor confidence and access to capital.
• The material weaknesses in internal controls over financial reporting could lead to inaccurate financial statements and regulatory issues.
• The company may be subject to an excise tax on share redemptions, which could reduce the value of its Class A common stock.
• The termination of a license agreement by Liminatus's partner could impact the business combination.

Future Outlook

The company's ability to continue as a going concern is dependent on completing the business combination by December 31, 2024. If the business combination is not completed, the company will cease operations and liquidate the trust account.

Management Comments

• Management has determined that the Company has and will continue to incur significant costs in pursuit of its acquisition plans which raises substantial doubt about the Company's ability to continue as a going concern.
• Management has determined that if the Company is unable to complete a Business Combination by December 31, 2024, then the Company will cease all operations except for the purpose of liquidating.

Industry Context

The report reflects the challenges faced by many SPACs in finding suitable merger targets and completing business combinations within the required timeframes. The delisting from Nasdaq and the subsequent trading on the OTC Pink Marketplace is a common outcome for SPACs that fail to meet listing requirements or complete a business combination in time.

Comparison to Industry Standards

• The financial performance of Iris Acquisition Corp is below average compared to other SPACs that have successfully completed business combinations.
• The company's high operating costs and significant net losses are not uncommon for SPACs in the pre-merger phase, but the magnitude of the losses and the working capital deficit are concerning.
• The multiple extensions of the business combination deadline and the delisting from Nasdaq are indicators of significant challenges in completing the transaction, which is not uncommon in the current SPAC market.
• The company's reliance on related party loans and the need for additional financing are also common among SPACs, but the level of debt and the uncertainty surrounding the business combination raise concerns about the company's financial stability.
• The material weaknesses in internal controls over financial reporting are a significant concern and are not typical for well-managed SPACs.

Related Party Transactions

• The company has a promissory note with a related party with a balance of $1,453,720.
• The company has received loans from its Sponsor for working capital and extension payments.

Stakeholder Impact

• Shareholders have experienced significant redemptions of their Class A common stock, reducing the number of outstanding shares.
• Shareholders have seen the company delisted from Nasdaq, which could negatively impact the value of their investment.
• Creditors may be at risk if the company is unable to complete its business combination and is forced to liquidate.
• Employees may face uncertainty about their future employment if the company is unable to continue as a going concern.

Next Steps

• The company needs to complete its business combination with Liminatus Pharma, LLC by December 31, 2024.
• The company needs to address the material weaknesses in its internal controls over financial reporting.
• The company needs to secure additional financing if required to complete the business combination or meet its obligations.
• The company needs to file a return and remit payment for any excise tax liability incurred.

Key Dates

Keywords

Business Combination, SPAC, Liminatus Pharma, Delisting, OTC Pink, Redemption, Working Capital, Net Loss, Financial Reporting, Internal Controls, Promissory Note, PIPE Investment